The Rapid Uptake Products (RUP) programme has been designed to support stronger adoption and spread of proven innovations.

RUP identifies and supports products with the National Institute for Health and Care Excellence (NICE) approval that support the NHS Long Term Plan’s key clinical priorities but have lower than expected uptake to date.

The current programme builds on the successes of previous RUPs programme, with themes selected via an open, staged, selection process.

The following innovations will be supported through the RUP Programme for 2021/22: 

Lipid Management: High Intensity Statins, Ezetimibe and PCSK9 inhibitors
The RUP for lipid management is a novel, NICE-endorsed clinical pathway. This innovation aims to improve a person’s lipid profile, by reducing cholesterol concentration in blood by treating patients with the right medicine along the evidence-based pathway. The pathway includes three medicines: high-intensity statins (HIST), ezetimibe, and PCSK9 inhibitors (continued from 2019/20). Bempedoic acid and inclisiran will be added to the pathway later in 2021.

Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath
FeNO (fractional exhaled nitric oxide) is a point of care test to measure type two inflammation in airways, which augments and supports the accuracy of asthma diagnosis. The aim of this innovation will be to improve patient care and outcomes by more effective diagnosis of patients suspected of having asthma.

We are hosting five regional collaborative forums to support the implementation of FeNO testing in South West England. Each forum is an opportunity to hear from South West respiratory leads and clinical champions about their experience and recommendations for implementing FeNO, and ask questions about implementation.

Watch the recording of the first forum held in November 2021. Our second forum is taking place on 20 January 2022. If you would like to attend please sign up via Eventbrite. Keep a lookout for details on further forums.

Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab
Biological therapies can transform patient lives by reducing long-term side effects of other treatments (e.g. oral corticosteroids (OCS)) and can also reduce the number of exacerbations and life-threatening asthma attacks. The aim of this innovation will be to improve patient care and outcomes by providing a better treatment option for patients with severe asthma. Read more about funding secured for the treatment of severe asthma in the South West region here.

Rapid Uptake Products Technical Note 2021 / 22
View the 2021-22 technical notes

Accelerated Access Collaborative (AAC)

The AHSN Network is a key member of the AAC, the umbrella organisation for UK health innovation, the front door to support for innovators and sets the strategy for a more effective innovation ecosystem. It makes it easier for innovators to navigate the UK healthcare system, streamline the development process for promising healthcare innovation, identify gaps in the UK’s innovation support offer and get breakthrough innovations into the NHS and to patients faster than previously. Find out more.